Idexx Laboratories price target raised to $640 from $540 at Stifel

Stifel raised the firm’s price target on Idexx Laboratories (IDXX) to $640 from $540 and keeps a Hold rating on the shares following a “solid” Q2. The standout Idexx premium in Q2 is a reason to increase bullishness around the company, according to the firm. However, Stifel contends that stock appreciation over the past three months likely captures a good amount of that excitement. The firm added that shares of Idexx Laboratories have outperformed the S&P 500 by 45% since early April and yet the company has only raised 2025 operational EPS by 1%.